Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 3/20 | 0.35 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ESRRG | P62508 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
| ▸ | FYN | P06241 | 1/20 | 0.32 |
| ▸ | GALR1 | P47211 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 3/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.31 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.31 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3680426 | 0.80 | MMP3 (0.41) | MEN1KMT2APTGS2ESR1ESR2 | |
| SCHEMBL3682703 | 0.77 | NPC1 (0.37) | ERN1PTGS2FYNESR1ESR2 | |
| SCHEMBL3723397 | 0.75 | ALDH1A1 (0.33) | MEN1KMT2APTGS2ESR1ESR2 | |
| SCHEMBL3682112 | 0.75 | ESR1 (0.38) | MEN1KMT2AESR1ESR2 | |
| SCHEMBL3646252 | 0.74 | L3MBTL1 (0.36) | MEN1KMT2APTGS2ESR2 | |
| SCHEMBL3683675 | 0.73 | ESR2 (0.36) | ESR1ESR2SENP1 | |
| SCHEMBL3676121 | 0.73 | ESR2 (0.36) | ESR1ESR2SENP1 | |
| SCHEMBL3684902 | 0.73 | ESR2 (0.36) | ESR1ESR2SENP1 | |
| SCHEMBL3681589 | 0.72 | ESR2 (0.35) | ESR1ESR2SENP1 | |
| SCHEMBL3679284 | 0.72 | ESR2 (0.38) | ESR1ESR2SENP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210524-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2010-08-19 | — | — | US | claimed |
| EP-2176209-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2010-04-21 | — | — | EP | claimed |
| WO-2009012954-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2009-01-29 | — | — | WO | claimed |
| US-20100210524-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2010-08-19 | — | — | US | disclosed |
| EP-2176209-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2010-04-21 | — | — | EP | disclosed |
| WO-2009012954-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210524-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | ESR1, ESRRA, ESR2 | ERN1 622/4885ACMSD 4054/4885MEN1 2945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.